Literature DB >> 143508

Biochemical aspects of Huntington's chorea.

T Caraceni, G Calderini, A Consolazione, E Riva, S Algeri, F Girotti, R Spreafico, A Branciforti, A Dall'olio, P L Morselli.   

Abstract

Fifteen patients affected by Huntington's chorea were divided into two groups, 'slow' and 'fast', according to IQ scores on the Wechsler-Bellevue scale, and scores on some motor performance tests. A possible correlation was looked for between some biochemical data (cerebrospinal fluid (CSF), homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5HIAA) levels, plasma dopamine-beta-hydroxylase (DBH), dopamine (DA) uptake by platelets), and clinical data (duration of illness, severity of symptoms, age of patients, IQ scores, 'slow' and 'fast' groups). The CSF, HVA, and 5HIAA levels were found to be significantly lowered in comparison with normal controls. DBH activity and DA uptake by platelets did not differ significantly from normal subjects. Treatment with haloperidol in all patients and with dipropylacetic acid in three patients did not appear to modify the CSF, HVA, and 5HIAA concentrations, the plasma DBH activity, or the DA uptake. There were no significant differences in the CSF, HVA, and 5HIAA contents between the two groups of patients, and there was no correlation between biochemical data and clinical features.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 143508      PMCID: PMC492765          DOI: 10.1136/jnnp.40.6.581

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

2.  Letter: Low GABA levels in CSF in Huntington's chorea.

Authors:  B S Glaeser; T A Hare; W H Vogel; D B Olewiler; B L Beasley
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

3.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

4.  A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.

Authors:  D L McLellan; R J Chalmers; R H Johnson
Journal:  Lancet       Date:  1974-01-26       Impact factor: 79.321

5.  Plasma uptake of dopamine and 5-hydroxytryptamine and plasma-catecholamine levels in patients with Huntington's chorea.

Authors:  M J Aminoff; A Trenchard; P Turner; W G Wood; M Hills
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

6.  Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study.

Authors:  P L McGeer; E G McGeer; H C Fibiger
Journal:  Neurology       Date:  1973-09       Impact factor: 9.910

7.  Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.

Authors:  E D Bird; L L Iversen
Journal:  Brain       Date:  1974-09       Impact factor: 13.501

8.  Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.

Authors:  A Barbeau; G Campanella; R F Butterworth; K Yamada
Journal:  Neurology       Date:  1975-01       Impact factor: 9.910

9.  Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.

Authors:  I Shoulson; R Kartzinel; T N Chase
Journal:  Neurology       Date:  1976-01       Impact factor: 9.910

10.  Regional distribution of choline acetyltransferase in the human brain: changes in Huntington's chorea.

Authors:  S M Aquilonius; S A Eckernås; A Sundwall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-07       Impact factor: 10.154

View more
  9 in total

1.  Oculomotor disorders in Huntington's chorea.

Authors:  G Avanzini; F Girotti; T Caraceni; R Spreafico
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-07       Impact factor: 10.154

2.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 3.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

4.  Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.

Authors:  F Girotti; F Carella; G Scigliano; M P Grassi; P Soliveri; P Giovannini; E Parati; T Caraceni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

5.  2-dimethylaminoethanol (Deanol) in Huntington's chorea.

Authors:  T A Caraceni; F Girotti; I Celano; E Parati; L Balboni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-12       Impact factor: 10.154

6.  Homovanilic acid in Huntington's disease and Sydenham's chorea.

Authors:  L Cunha; C R Oliveira; M Diniz; R Amaral; A F Conçalves; J Pio-Abreu
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-03       Impact factor: 10.154

7.  Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice.

Authors:  Fanny Mochel; Brandon Durant; Alexandra Durr; Raphael Schiffmann
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

8.  A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Authors:  Xin Du; Terence Y C Pang; Anthony J Hannan
Journal:  Front Neurol       Date:  2013-07-09       Impact factor: 4.003

Review 9.  Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms.

Authors:  Patrick Pla; Sophie Orvoen; Frédéric Saudou; Denis J David; Sandrine Humbert
Journal:  Front Behav Neurosci       Date:  2014-04-23       Impact factor: 3.558

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.